Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANV419 Monotherapy and Combinations in Relapsed/Refractory Multiple Myeloma
NCT05641324Phase 1Terminated
- Sponsor
- Anaveon
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of ANV419 in multiple myeloma (MM), sponsored by Anaveon. Primary endpoint: Adverse Events at 1 year. Started Feb 2023; status: terminated.
02
Drugs
ANV419
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05641324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641324.